Elite Pharmaceuticals Inc. (OTCMKTS:ELTP - Get Free Report)'s share price fell 3.5% on Monday . The stock traded as low as $0.52 and last traded at $0.54. 249,673 shares traded hands during trading, a decline of 80% from the average session volume of 1,247,401 shares. The stock had previously closed at $0.56.
Elite Pharmaceuticals Stock Down 3.5%
The company has a quick ratio of 3.50, a current ratio of 4.88 and a debt-to-equity ratio of 0.08. The business has a fifty day moving average of $0.60 and a two-hundred day moving average of $0.51.
Elite Pharmaceuticals (OTCMKTS:ELTP - Get Free Report) last announced its earnings results on Monday, June 30th. The specialty pharmaceutical company reported $0.01 EPS for the quarter. The business had revenue of $32.00 million during the quarter. Elite Pharmaceuticals had a positive return on equity of 3.96% and a negative net margin of 5.13%.
About Elite Pharmaceuticals
(
Get Free Report)
Elite Pharmaceuticals, Inc, a specialty pharmaceutical company, engages in the development, manufacture, and sale of oral, controlled-release products, and generic pharmaceuticals. The company operates in two segments, Abbreviated New Drug Applications for Generic Pharmaceuticals and New Drug Applications for Branded Pharmaceuticals.
Further Reading
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Elite Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Elite Pharmaceuticals wasn't on the list.
While Elite Pharmaceuticals currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
